Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9649661rdf:typepubmed:Citationlld:pubmed
pubmed-article:9649661lifeskim:mentionsumls-concept:C0033860lld:lifeskim
pubmed-article:9649661lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:9649661lifeskim:mentionsumls-concept:C1155266lld:lifeskim
pubmed-article:9649661lifeskim:mentionsumls-concept:C0220905lld:lifeskim
pubmed-article:9649661pubmed:issue1lld:pubmed
pubmed-article:9649661pubmed:dateCreated1999-1-19lld:pubmed
pubmed-article:9649661pubmed:abstractTextTopical application of 1alpha,25-dihydroxyvitamin D3 (VD3) is thought to be beneficial in psoriasis because of its action in regulating keratinocyte proliferation and inflammation mediated by various cytokines. We assessed the effect of VD3 on the production levels of interferon (IFN)-alpha, interleukin (IL)-6, IL-8 and tumor necrosis factor (TNF)-alpha in mitogen-stimulated peripheral blood mononuclear cells (PBMC) of psoriatic patients. The results demonstrated that VD3 significantly inhibited IFN- , IL-6, and IL-8 levels produced by concanavalin A (Con A)-stimulated PBMC of psoriatic patients in a dose-dependent manner, and reduced mRNA expression for IFN- and IL-8. These findings suggest that in addition to the direct anti-proliferation effect on keratinocytes, VD3 may down-regulate the inflammatory cytokine production by infiltrating cells in psoriatic lesions.lld:pubmed
pubmed-article:9649661pubmed:languageenglld:pubmed
pubmed-article:9649661pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9649661pubmed:citationSubsetIMlld:pubmed
pubmed-article:9649661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9649661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9649661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9649661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9649661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9649661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9649661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9649661pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9649661pubmed:statusMEDLINElld:pubmed
pubmed-article:9649661pubmed:issn1167-1122lld:pubmed
pubmed-article:9649661pubmed:authorpubmed-author:InoueMMlld:pubmed
pubmed-article:9649661pubmed:authorpubmed-author:IwatsukiKKlld:pubmed
pubmed-article:9649661pubmed:authorpubmed-author:MatsuiTTlld:pubmed
pubmed-article:9649661pubmed:authorpubmed-author:KanekoFFlld:pubmed
pubmed-article:9649661pubmed:authorpubmed-author:NiheiYYlld:pubmed
pubmed-article:9649661pubmed:authorpubmed-author:NishibuAAlld:pubmed
pubmed-article:9649661pubmed:issnTypePrintlld:pubmed
pubmed-article:9649661pubmed:volume8lld:pubmed
pubmed-article:9649661pubmed:ownerNLMlld:pubmed
pubmed-article:9649661pubmed:authorsCompleteYlld:pubmed
pubmed-article:9649661pubmed:pagination16-20lld:pubmed
pubmed-article:9649661pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:meshHeadingpubmed-meshheading:9649661-...lld:pubmed
pubmed-article:9649661pubmed:articleTitleRegulatory effects of 1alpha,25-dihydroxyvitamin D3 on inflammatory responses in psoriasis.lld:pubmed
pubmed-article:9649661pubmed:affiliationDepartment of Dermatology, Fukushima Medical College, Hikarigaoka-1, Fukushima 960-1295, Japan.lld:pubmed
pubmed-article:9649661pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9649661pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9649661pubmed:publicationTypeControlled Clinical Triallld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:9649661lld:pubmed